Takeda Launches New Subsidiary in Ecuador

                  Takeda Launches New Subsidiary in Ecuador

  PR Newswire

  ZURICH, Switzerland, March 21, 2013

ZURICH, Switzerland, March 21, 2013 /PRNewswire/ --

Demonstrates Takeda's long-term commitment to the Latin American market

Takeda Pharmaceuticals International GmbH ("Takeda"), today announced further
expansion of its presence in Latin America with the launch of its wholly-owned
subsidiary in Ecuador. Takeda Ecuador S.A. (Takeda Ecuador or "the Company")
will be headquartered in Quito and will be responsible for the sales and
marketing of Takeda's products in Ecuador.

Takeda is building a leading position in Latin America. It has a direct
presence in Brazil, Mexico, Argentina, Venezuela, Colombia and Ecuador, and is
looking at opportunities to further expand its footprint in the region.
According to IMS Health, pharmaceutical sales in Latin America totaled US$
74.5 billion in 2012 and are expected to grow at a compound annual rate of 8%*
between 2012 and 2016. Takeda plans to outgrow the market over the same

Ecuador is a dynamic and growing market, driven by government investment and
strong oil and mining industries. The country's GDP totalled more than US$ 70
billion in 2012 while pharmaceutical sales in amounted to US$1.27 billion and
are expected to continue to grow by 10% during 2013*. 

In line with the Takeda's emerging markets strategy, Takeda Ecuador is
building a product portfolio based on the medical needs of the population,
focusing on gastroenterology, cardiology, metabolism, oncology and respiratory
diseases. The Company will initially focus on Zurcal ( pantoprazole ), Faktu (
Policresulen, Cinchocaine hydrochloride) , Alevian Duo® ( Pinaverium bromide,
Dimeticone ) and Tecta® (p antoprazole magnesium ) and its gynaecology
product, Albothyl ( Policresulen ), which Takeda repatriated following the
Nycomed acquisition.

Takeda Ecuador plans to leverage its sales platform with a steady stream of
product launches from its existing portfolio and R&D pipeline.

Carlos Haro has been appointed country manager for Ecuador. He joins the
Company from Sanofi, where he was the General Manager for Ecuador. He will
lead the start-up team which will grow steadily as the Company expands its
portfolio and enters new therapeutic areas.

"The launch of our subsidiary in Ecuador reinforces Takeda's position in Latin
America and will enable us to meet the diverse healthcare needs of the
population. We have an established product portfolio, which will give us a
strong starting point and we look forward to launching our novel medicines
into the market," said Norbert Oppitz, Senior Vice President, Latin America,
at Takeda "This investment further demonstrates our commitment to Latin
America and its growth potential. We have ambitious plans in this region and
we continue to evaluate opportunities to expand our footprint."

^* Data Source:© 2012 IMS Health. All rights reserved. Estimate based on
Market Prognosis Global 2012-2016. 

About Takeda Pharmaceuticals International GmbH

Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a
wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As the
largest pharmaceutical company in Japan and a leader in the global industry,
Takeda's mission is to strive toward better health for patients worldwide
through leading innovation in medicine. It has a commercial presence in around
70 countries, with particular strength in Asia, North America, Europe and
fast-growing emerging markets including Latin America, Russia-CIS and China.
Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th
in Europe. Areas of focus include cardiovascular and metabolic diseases,
immunology and respiratory diseases, oncology and central nervous system
diseases, among others. Through the integration of Millennium Pharmaceuticals
and Nycomed, Takeda has been transforming itself, broadening its therapeutic
expertise and geographic outreach.

Additional information about Takeda is available through its corporate
website, http://www.takeda.com

This press release has been issued by Takeda Pharmaceuticals International
GmbH, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.

Contact: Contact: Takeda Pharmaceuticals International GmbH, Birgit
Gronkowski, +41-44-555-1506, Birgit.Grokowski@takeda.com; Takeda Mexico,
Norbert Oppitz, +52-55-5387-9330 ext. 2470, Norbert.Oppitz@takeda.com
Press spacebar to pause and continue. Press esc to stop.